A5006096603- Systemic Lupus Erythematosus Research
- Monoclonal and Polyclonal Antibodies Research
- Inflammatory Myopathies and Dermatomyositis
- Renal Diseases and Glomerulopathies
- T-cell and B-cell Immunology
- Atherosclerosis and Cardiovascular Diseases
- Systemic Sclerosis and Related Diseases
- Liver Diseases and Immunity
- Biomarkers in Disease Mechanisms
- Immunodeficiency and Autoimmune Disorders
- Rheumatoid Arthritis Research and Therapies
- Peripheral Neuropathies and Disorders
- Eosinophilic Disorders and Syndromes
- Chronic Lymphocytic Leukemia Research
- Cytokine Signaling Pathways and Interactions
- Liver Disease Diagnosis and Treatment
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Skin Diseases and Diabetes
- Muscle Physiology and Disorders
- Lymphoma Diagnosis and Treatment
- Protein Tyrosine Phosphatases
- Inflammasome and immune disorders
- Reproductive System and Pregnancy
- Pregnancy and Medication Impact
- Autoimmune Bullous Skin Diseases
University of Padua
2016-2025
University of Turin
2023-2025
A. O. Ordine Mauriziano di Torino
2024-2025
University of Gothenburg
2022-2023
Pakistan Institute of Medical Sciences
2023
Pfizer (United States)
2021
Roche (Switzerland)
2021
Deutsche Forschungsgemeinschaft
2021
Novartis (Switzerland)
2021
Galapagos (Belgium)
2021
To assess the prevalence of prolonged remission in Caucasian patients affected with systemic lupus erythematosus (SLE) and its relationship damage accrual.Caucasian diagnosed SLE between 1990 2009 quarterly seen from to 2013 were included study. We defined as when lasting ≥5 consecutive years. Three levels using Disease Activity Index-2000 (SLEDAI-2K): complete remission: no disease activity corticosteroid-free immunosuppressant-free patients; clinical off corticosteroids: serologically...
To evaluate the prevalence, duration and effect on damage accrual of 'Lupus Low Disease Activity State' (LLDAS) in a monocentric cohort patients with systemic lupus erythematosus (SLE).We studied 293 Caucasian SLE during 7-year follow-up period. activity was assessed by Index 2000 (SLEDAI-2K) SELENA-SLEDAI physician global assessment (PGA), Systemic Lupus International Collaborating Clinics/American College Rheumatology Damage (SDI). We considered following definition LLDAS: SLEDAI-2K ≤4...
Objectives To evaluate changes in demographic, clinical and histological presentation, prognosis of lupus nephritis (LN) over time. Patients methods We studied a multicentre cohort 499 patients diagnosed with LN from 1970 to 2016. The 46-year follow-up was subdivided into three periods (P): P1 1970–1985, P2 1986–2001 P3 2002–2016, accordingly grouped based on the year diagnosis. Predictors patient renal survival were investigated by univariate multivariate proportional hazards Cox regression...
Objective To investigate effectiveness and safety of belimumab in patients with active systemic lupus erythematosus (SLE) a clinical practice setting. Methods Sixty‐seven SLE, mean ± SD age 39.3 10.2 years, from 2 Italian prospective cohorts were treated (10 mg/kg on day 0, 14, 28, then every 28 days) added to background therapy. The Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI‐2K), the International Collaborating Clinics/American College Rheumatology Damage Index, Score...
To identify the shortest duration of remission associated with improved outcomes in systemic lupus erythematosus (SLE).We studied 293 Caucasian patients SLE during 7-year follow-up. Disease activity was assessed by Activity Index 2000 and damage Systemic Lupus International Collaborating Clinics/American College Rheumatology Damage (SDI). We defined three levels: complete, clinical off-corticosteroids, on-corticosteroids (prednisone 1-5 mg/day). The effect different durations (1, 2, 3, 4 ≥5...
To evaluate the role of serum IgG, IgM and IgA anti-dsDNA antibody isotypes in diagnosis systemic lupus erythematosus (SLE), their association with clinical features disease activity, a large cohort SLE patients.Sera 200 patients (mean age 34±10.3 years; 26 male 174 female; median duration 115 months, range 7-378), 206 controls, including 19 Sjögren's syndrome, 27 rheumatoid arthritis, psoriatic 15 idiopathic inflammatory myopathies (IIM), 13 sclerosis, 49 infectious diseases 57 healthy...
To investigate predictors of response, remission, low disease activity, damage, and drug discontinuation in patients with systemic lupus erythematosus (SLE) who were treated belimumab.In this retrospective study a multicenter cohort SLE received intravenous belimumab, the proportion achieved treatment response according to Responder Index 4 (SRI-4) was determined, Systemic Lupus International Collaborating Clinics/American College Rheumatology Damage (SDI) used score damage yearly over...